Showing 4891-4900 of 5910 results for "".
- Kerry Solomon First in US to Implant Alcon’s Vivity IOLhttps://modernod.com/news/kerry-solomon-first-in-nation-to-implant-alcons-vivity-iol/2478619/Kerry Solomon, MD, partner at Carolina Eyecare Physicians, Charleston, South Carolina, is the first in the United States following FDA approval to complete surgery using Alcon’s AcrySof IQ Vivity Extended Range of Vision IOL, according to a news release. “The Vivity lens is a remarka
- Market Scope: Cornea Products Market to Grow an Estimated 6.1 Percent Through 2025https://modernod.com/news/market-scope-cornea-products-market-to-grow-an-estimated-6-1-percent-through-2025/2478618/Expanding use of products to treat many corneal diseases will increase the role of devices and surgery in the cornea treatment landscape, according to Market Scope. Over 1 billion people are affected by 50 corneal diseases that cause cornea impairment, including corneal ectasias, dystrophies, ker
- Medicare Cuts Jeopardize Patient Care and Ignore Impacts of Pandemichttps://modernod.com/news/medicare-cuts-jeopardize-patient-care-and-ignore-impacts-of-pandemic/2478611/The Medicare Physician Fee Schedule (MPFS) final rule released today by the Centers for Medicare & Medicaid Services (CMS) will harm patients and further destabilize a health care system already under severe strain from the pandemic, according to a Surgical Care Coalition news release.
- UK Authorizes Use of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/uk-authorizes-use-of-pfizer-biontechs-covid-19-vaccine/2478614/The UK government said Wednesday that it accepted a recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to grant temporary authorization of Pfizer and BioNTech’s mRNA-based COVID-19 vaccine BNT162b2. A Department of Health and Social Care spokesperson said 
- Roche Receives FDA Emergency Use Authorization for New COVID-19 Antibodies Testhttps://modernod.com/news/roche-receives-fda-emergency-use-authorization-for-new-covid-10-antibodies-test/2478610/Roche announced that its Elecsys Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the FDA. The semi-quantitative serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus. The new test tar
- Orbis International Announces Mary Jane Jamar as First Chief Human Resources Officerhttps://modernod.com/news/orbis-international-announces-mary-jane-jamar-as-first-chief-human-resources-officer/2478605/Orbis has named Mary Jane Jamar as the organization’s first Chief Human Resources Officer (CHRO). In this capacity, Ms. Jamar will also join and play a critical role on the Orbis Executive Leadership Team.
- Heidelberg Engineering Names New Scientific Directorhttps://modernod.com/news/heidelberg-engineering-names-new-scientific-director/2478603/Charles Reisman has joined Heidelberg Engineering’s global management team as Scientific Director. In this newly created role, he will be responsible for the clinical research plan that directly feeds into the product development pipeline. Mr. Reisman is an accomplished clinical validation
- Vitamin Sciences Lauches Visivite Blue Light Basher Ocular Supplementhttps://modernod.com/news/vitamin-sciences-lauches-visivite-blue-light-basher-ocular-supplement/2478604/Vitamin Science has added to its arsenal of quality ocular supplements with its launch of VisiVite Blue Light Basher earlier this year. High energy blue light is everywhere—cell phones, TV’s, LED lights and sunlight itself. To
- John Weiss Secures Exclusive UK Distributorship for VRmagic’s Eyesi Surgical Medical Simulatorhttps://modernod.com/news/john-weiss-secures-exclusive-uk-distributorship-for-vrmagics-eyesi-surgical-medical-simulator/2478600/John Weiss & Son has announced it has secured an exclusive distributorship for the VRmagic Eyesi Surgical medical simulator. VRmagic was established in 2001 and is a provider of virtual and augmented reality technology in medical training. The solutions developed by VRmagic permit a re
- Moderna’s mRNA COVID-19 Vaccine 94.1% Effective at Final Analysishttps://modernod.com/news/modernas-mrna-covid-19-vaccine-94-1-effective-at-final-analysis/2478596/Moderna announced Monday that the primary efficacy analysis of the phase 3 COVE study showed that its experimental mRNA-based COVID-19 vaccine mRNA-1273 had an efficacy rate of 94.1%, confirming the level observed at the first interim analysis. The company noted that the latest data were based on